![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2008 Neoplasia Press, Inc. All rights reserved Co-opted JNK/SAPK Signaling in Wnt/β-catenin-Induced Tumorigenesis1 *Department of Biomedical Genetics, University of Rochester Medical Center, 601 Elmwood Avenue, BOX 611, Rochester, NY 14642, USA †Center for Oral Biology, University of Rochester Medical Center, 601 Elmwood Avenue, BOX 611, Rochester, NY 14642, USA ‡James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, BOX 611, Rochester, NY 14642, USA §Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, BOX 611, Rochester, NY 14642, USA Address all correspondence to: Wei Hsu, 601 Elmwood Avenue, BOX 611, Rochester, NY 14642. E-mail: Wei_Hsu/at/urmc.rochester.edu Received May 7, 2008; Revised June 19, 2008; Accepted June 23, 2008. This article has been cited by other articles in PMC.Abstract Aberrant stimulation of the canonical Wnt pathway induces mammary tumorigenesis in mice. It has been well documented that two types of tumors, adenocarcinoma and adenocarcinoma with squamous metaplasia, develop in these mutants. However, the molecular mechanism underlying the induction of squamous transdifferentiation remains largely unknown. Here, we show that JNK/SAPK signaling plays an important role in Wnt-dependent mammary development and malignant transformation. The JNK/SAPK pathway is stimulated in pregnancy-mediated lobulo-alveolar morphogenesis, a process highly dependent on Wnt/β-catenin signaling. Strong elevations of JNK/SAPK signaling are associated with squamous metaplasia of the Wnt-induced adenocarcinoma. Reconstitution of β-catenin and JNK/SAPK signaling activities also promotes expression of the squamous cell marker in cultured epithelial cells. Furthermore, a synergistic activation of these two pathways can be identified in the malignant squamous cells of human endometrial and lung cancers. This is potentially a significant discovery in modern cancer therapy because of the effectiveness of an angiogenesis inhibitor, Avastin, for the treatment of adenocarcinoma, but not squamous cell carcinoma, in human lung cancers. Our finding may improve the usage of biomarkers to distinguish these two poorly differentiated tumor types, sharing similar histologic features. Introduction Wnt signaling is important for diverse processes during embryonic, fetal, and postnatal development [1]. Deregulation of Wnt signaling has also been linked to pathogenesis of various diseases [2]. β-Catenin, a key component of adherens junction, plays an essential role in transduction of the canonical Wnt pathway [3]. The cellular level of β-catenin is controlled by a disruption complex, including Axin, APC, and GSK-3β [4]. In the absence of a Wnt signal, this complex binds to β-catenin, mediating its phosphorylation and degradation through the ubiquitin-mediated proteolysis system [5]. Wnt signals perturb the formation of the disruption complex by activating the upstream regulators, leading to nuclear accumulations of β-catenin [6]. The downstream signaling events are triggered by its interaction with transcription factors of the lymphoid enhancer factor/T cell factor (LEF/TCF) family to regulate target gene expression [7]. Wnt signaling is intimately involved in the development and neoplastic transformation of the mammary gland [8]. Several members of the Wnt family are expressed in the epithelium and stromal compartments at various stages of mammary development [9]. It has been well established that aberrant stimulation of the canonical Wnt pathway, such as transgenic expression of Wnt1, Wnt10b, results in mammary tumorigenesis in mice [10,11]. Expression of a degradation-deficient form of β-catenin leads to the formation of mammary tumors in mice [12]. Transgenic mice with elevated levels of the Wnt target cyclin D1 or c-myc also develop mammary tumors [13,14]. Furthermore, Wnt signals are required not only for induction but also for the inhibition of mammary development. The loss of Wnt4 impairs the early phases of pregnancy-dependent mammary morphogenesis [15]. In contrast, Wnt5a-null mammary tissue exhibits an accelerated cell growth and proliferation capacity [16]. This probably is due to the involvement of Wnt5a in an alternative pathway (see below). Reduction of Wnt/β-catenin signaling by high levels of Axin or a dominant-negative β-catenin interferes with alveolar morphogenesis at late pregnancy stages [17,18]. The loss of LEF-1 transcription factor in mice led to the lack of mammary bud formation at embryogenesis [19]. These studies imply that Wnt signaling is critical for mammary development in health and disease. In addition to β-catenin, Wnt signals have been shown to transduce through alternative pathways [20,21]. Wnt5a, Wnt5b, and Wnt11 are representatives of noncanonical Wnt signaling through JNK/SAPK (Jun N-terminal kinase/stress-activated protein kinase), a cascade similar to the planer cell polarity pathway in Drosophila. Aberrant activation of Wnt/JNK pathway seems to develop more malignant phenotypes, such as abnormal tissue polarity, invasion, and metastasis [21]. Stimulation of Wnt5a has been associated with various types of human cancers, including gastric cancer, lung cancer, and melanoma. There are a few molecules playing an essential role in both canonical and noncanonical pathways, suggesting that the Wnt signal might diverge at these transducers. Both Dsh/Dvl and Axin have been shown to activate Wnt/JNK signaling cascade through domains distinct from those regulating β-catenin [22]. Axin induces JNK/SAPK activity through its MEKK1 binding and self-association domains [23]. These domains do not seem to be required for down-regulation of β-catenin in Xenopus axis determination [24]. In Drosophila, the DIX domain of Dsh is dispensable for the planer cell polarity pathway, whereas it is essential for β-catenin signaling [25]. The dual role of signal transducers raises the question of overlap between the Wnt pathways, as well as other signaling pathways. However, the significance of cross-signaling interaction in normal developmental processes and pathogenesis of human diseases remains largely elusive. In this study, we investigated the potential role of JNK/SAPK signaling in Wnt-dependent mammary development and tumorigenesis in mice. The JNK and its related p38 MAP kinases were stimulated during pregnancy-mediated lobulo-alveolar morphogenesis, a process highly dependent on Wnt/β-catenin signaling. In the hyperplasia and adenocarcinoma caused by high levels of Wnt, JNK/SAPK signaling apparently was not induced. However, the Wnt/JNK pathway was strongly stimulated in squamous metaplasia, a process in which the presence of glandular epithelium is replaced by squamous epithelium, suggesting its involvement in the transdifferentiation of malignant cells. Reconstitution of β-catenin and JNK/SAPK signaling activities promoted expression of squamous cell markers in cultured epithelial cells. Furthermore, our finding led us to identify that these two pathways are synergistically activated in the malignant squamous cells of human endometrial and lung cancers. Our results suggest that JNK/SAPK signaling not only has a crucial function in squamous cell differentiation but also plays a co-opted role in the Wnt/β-catenin-mediated oncogenic transformation. Materials and Methods Animals and Human Samples MMTV-Wnt1 mice, expressing Wnt1 under control of theMMTV promoter, were generated and described previously [26]. Briefly, mammary hyperplasia could be detected in all of the transgenic animals. Approximately 50% of the females developed mammary tumor at 3 to 6 months of age. Mice carrying the MMTV-Wnt1 transgene were genotyped by polymerase chain reaction analysis using primers (5′-ggacttgcttctcttctcatagcc-3′ and 5′-ccacacaggcatagagtgtctgc-3′) to identify the transgene. The polymerase chain reaction was performed by denaturation at 94°C for 2 minutes and 34 cycles of amplification (94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 45 seconds), followed by a 2-minute extension at 72°C. Care and use of experimental animals described in this work comply with guidelines and policies of the University Committee on Animal Resources at the University of Rochester. The paraffin sections of human endometrial and lung cancers were obtained based on a protocol approved by University of Rochester Research Subjects Review Board. The identifiers of all patients have been removed to protect confidentiality. The study, approved by the program director at the National Cancer Institute, was judged “NO” for human subject research because we could not have an intervention with a living person and would not receive or record any identifiable information. Cells and DNA C57MG and C57MG-Wnt1 mammary epithelial cell lines were obtained from Arnold Levine [27]. Cells were cultured with DMEM containing 10% FCS, 100 U of penicillin, and 100 mg/ml streptomycin in a humidified 5% CO2 incubator at 37°C. The pcatC-Lef1 is a DNA plasmid containing the C-terminal activation domain of human β-catenin (amino acids 696–781) fused to the amino terminus of LEF-1 [28]. The pCMV-ΔMEKK1 contains a dominant/constitutively active form of MEKK1 under control of a CMV promoter [29]. The pCMV-SEKED is a plasmid permitting the expression of a partially active SEK1 [30]. Approximately 2 x 104 cells were plated 24 hours before transfection. Introduction of DNA plasmids (0.5 µg per plasmid) into the cultured cells was performed by Lipofectamine 2000-mediated transfection according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). Cells were harvested 24 hours after the transfection. Histologic Diagnosis, Immunostaining, and Immunoblot Samples were fixed, paraffin-embedded, sectioned, and stained with hematoxylin/eosin for histologic evaluation as described [31,32]. Tissue sections were subject to immunologic staining with avidin/biotinlylated enzyme complex or indirect fluorescent staining as described [17,33,34]. Briefly, samples were deparaffinized and hydrated, followed by antigen unmasking (Vector Laboratories, Burlingame, CA). Endogenous peroxidase activity was blocked by incubating sections with 3% hydrogen peroxide. For the use of mouse primary antibodies, sections were incubated with mouse IgG blocking solution (Vector Laboratories). After addition of primary antibodies for 30 minutes at room temperature, sections were incubated with horseradish peroxidase-conjugated secondary antibodies for 10 minutes at room temperature. The staining was then visualized by enzymatic color reaction according to the manufacturer's specification (Vector Laboratories). Images were analyzed using an Axio Observer microscope and a SPOT-RT camera (Carl Zeiss, Thornwood, NY). For immunoblot analysis, cells were lysed with M-PER reagent (78501; Pierce, Rockford, IL), containing protease inhibitor cocktail (diluted at 1:100, P8340; Sigma, St. Louis, MO), for 5 minutes with gentle shaking. Cell lysates were subject to immunoblot analysis as described [35,36]. Bound primary antibodies were detected with horseradish peroxidase-conjugated secondary antibodies, followed by enhanced chemical luminescence-mediated visualization (Amersham, Piscataway, NJ) and autoradiography. Mouse monoclonal antibodies actin (Lab Vision, Fremont, CA), ABC (Upstate, Billerica, MA), and HMW-Keratin (Lab Vision); rabbit polyclonal antibodies cyclin D1 (Lab Vision), β-catenin (Lab Vision), PJNK (Cell Signaling, Danvers, MA), Pp38 (Cell Signaling), PErk1/2 (Cell Signaling), PJun63 (Cell Signaling), and PJun73 (Cell Signaling) were used as primary antibodies. Results JNK/SAPK Signaling in Mammary Development To investigate the involvement of JNK/SAPK signaling in mammary development, we examined the expression of phosphorylated forms of JNK/SAPK signaling molecules. Immunostaining of phosphorylated JNK (PJNK) did not show its presence in nulliparous glands at 3 months (Figure 1A
Stimulation of JNK/SAPK Signaling in Squamous Metaplasia We next determined whether JNK/SAPK signaling plays a role in Wnt-induced mammary tumorigenesis by examining MMTV-Wnt1 mice, in which Wnt1 is expressed constitutively under control of the mouse mammary tumor virus (MMTV) promoter. Consistent with the importance of β-catenin.mediated malignant transformation, β-catenin became nuclearly localized in the hyperplastic epithelia, before the onset of tumorigenesis, induced by MMTV-Wnt1 (Figure 2G
In MMTV-Wnt1 mice, two types of mammary tumors, adenocarcinoma (AC) and adenocarcinoma with squamous metaplasia (SM), were identified usually after 3 months (Figure 3
To further elucidate the mechanism underlying Wnt-mediated oncogenic transformation, we studied whether the activation of JNK/SAPK signaling is associated with this process. Similar to what was observed in the Wnt-induced hyperplasia, the expression of PJNK, Pp38 and PJun73 also was not detected in AC (Figure 3 Molecular Mechanism of JNK/SAPK Activation To examine whether activation of Wnt/β-catenin signaling has any effects on JNK/SAPK signaling, a dominant-negative form of Axin (dnAxin) and a fusion protein of β-catenin and LEF1 (catCLEF1) were used to induce this signaling pathway. The catCLEF1 protein is a chimera, which links the C-terminal activation domain of human β-catenin to the N-terminus of LEF-1 and constitutively induces transcription of downstream genes [28]. In cells expressing catCLEF1, we detected a higher-molecular weight protein, presumably the chimera, using an antibody recognizing a nonphosphorylated/stabilized form of β-catenin (Figure 4A
We next investigated at which molecular level the signaling activation is required to stimulate both JNK and p38. Dominant forms of MEKK1 (Δ-MEKK1) and SEK1 (SEKED) were used to activate the downstream signaling cascade. MEKK1 is an MAPKKK which turns on JNK through activation of SEK1 (a MAPKK also known as MKK4) [41,42]. The expression of dominant SEK1 had no significant effects on the phosphorylation of JNK, and c-Jun at Ser63 and Ser73, but slightly enhanced the phosphorylation of p38 (data not shown). However, the phosphorylation of p38, JNK, and c-Jun at Ser63 and Ser73 was strongly stimulated by the dominant MEKK1 (Figure 4A On the basis of prior reports, this could be achieved by activation of Axin. However, we failed to detect stimulation of JNK/SAPK signaling by high levels of Axin. The result is contradictory to the previous observations, suggesting that activation of JNK/SAPK signaling is at the level upstream of Axin. Alternatively, a second signal parallel to the Wnt pathway may be required. We then examined if overexpression of Wnt is sufficient to stimulate JNK/SAPK signaling. In cells transfected by Wnt1, we detected similar results to those observed in the dnAxin-expressing cells (Figure 4B Induction of Squamous Differentiation by Wnt/β-catenin and JNK/SAPK Pathways On the basis of the above discovery, we hypothesized that simultaneous stimulation of Wnt/β-catenin and stress signaling promotes squamous differentiation of epithelial cells. We therefore used a cell culture system, which is more amenable to reconstituting the molecular events. First, the C57MG mammary epithelial cell line was examined for the status of Wnt/β-catenin and JNK/SAPK signaling. The JNK/SAPK signaling activity was apparently detected in C57MG cells as PJun73 was detected in every single cell whereas PJun63 was positive in only a few cells (Figure 5
To further confirm that squamous differentiation is promoted by a synergistic activation of both pathways, we transiently expressed catCLEF1 and ΔMEKK1 to induce Wnt/β-catenin and JNK/SAPK signaling, respectively. The catCLEF1 protein constitutively induces transcription of the Wnt downstream genes [28] whereas ΔMEKK1 constitutively activates JNK/SAPK signaling [29]. High levels of HMW-K were detected in the C57MG cells expressing catCLEF1 and ΔMEKK1, indicating squamous differentiation (Figure 5 Activation of JNK/SAPK and Wnt/β-Catenin in Human Endometrial and Lung Cancers Squamous metaplasia rarely develops in human breast cancers but is often found in other types of tumors including endometrial and lung cancers. Activation of Wnt/β-catenin signaling has been linked in the development of these cancers [43–48]. Therefore, we tested if our finding has a general implication in development of human cancers. We first screened samples of human endometrioid adenocarcinoma with squamous metaplasia (Figure 6A
Discussion The present study shows that stress signaling is stimulated during normal development as well as neoplastic transformation of the mammary gland. The JNK/SAPK and p38 MAPK cascades are strongly activated in the lobulo-alveolar cells during pregnancy-mediated mammary development. This developmental process is highly dependent on the canonical Wnt pathway as we and others demonstrated previously [12,17,18]. As an alternative pathway of Wnt, JNK/SAPK might coordinate with the canonical pathway to modulate alveolar morphogenesis. Whereas β-catenin signaling is known to expand the cell population, a second pathway might be important for the differentiation process. It has been well recognized that activation of the canonical Wnt pathway is tightly associated with the malignant squamous phenotype [10,13,39,49]. However, the molecular mechanism underlying the squamous metaplasia mediated by high levels of Wnt/β-catenin signaling remains elusive. We have identified JNK/SAPK as a candidate pathway for the secondary signaling cascade involved in squamous differentiation. In the Wnt-induced tumorigenesis, JNK/SAPK signaling is silent in hyperplasia and adenocarcinoma but is highly elevated in cells undergoing squamous differentiation. Reconstitution of these molecular events by synergistic activation of β-catenin and JNK/SAPK signaling promotes squamous differentiation in C57MG mammary epithelial cells, suggesting a co-opted role of the JNK/SAPK signaling cascade in Wnt-mediated oncogenic transformation. We have extended our findings into the biology of human cancers by showing that coordinated stimulation of these two pathways is correlated with development of the malignant squamous cell type in human endometrial and lung cancers. In addition, the JNK/SAPK signaling molecules may serve as biomarkers for identifying the malignant squamous cell types in human cancers. This is of important clinical significance with the advancement in modern cancer therapy. In the past, it was sufficient to divide human lung cancers into small cell and non-small cell types with the latter comprised mostly of adenocarcinoma and squamous carcinoma. That was the era when the therapeutic choice for small cell carcinoma was chemoradiation, whereas adenocarcinoma and squamous carcinoma were similarly treated with surgery. A new angiogenesis inhibitor, Avastin, is effective only for adenocarcinoma of the lung but has the potential to cause fetal pulmonary hemorrhage in patients with squamous cell carcinoma. Since the advent of this drug, it has become critical to separate these two tumor types. However, adenocarcinoma and squamous cell carcinoma, sharing similar histologic features, can be difficult to distinguish when they are poorly differentiated. It would be interesting to determine whether the JNK/SAPK signaling molecules can be used as additional markers for differential diagnosis. The study may also shed light on the molecular pathogenesis of these two tumor types in lung. A previous report indicated that Wnt5a up-regulated in human oral cancers is a potential marker of the malignant phenotype of squamous cell carcinoma [50]. Because Wnt5a is a member of noncanonical Wnt, the data support the notion of co-opted JNK/SAPK signaling in Wnt-induced tumorigenesis. Activation of the JNK/SAPK pathway was shown to mediate the expression of a squamous cell marker SPRR1B in respiratory injuries caused by environmental pollutants [51,52]. In a rat model of tobacco smoke-induced cell proliferation and squamous metaplasia, the JNK/SAPK signaling cascade and cyclin D1 expression were also stimulated [53]. Indeed, Wnt/β-catenin signaling was shown to be activated in cigarette smoke-induced lung tumorigenesis, further supporting our hypothesis [54]. In addition, targeted disruption of Wnt7b in mice caused lung hypoplasia due to defects in mesenchymal proliferation [55]. Wnt/β-catenin signaling is also required for branching morphogenesis and cell type specification of embryonic lung development [56–58]. It has been suggested that Wnt/JNK signaling could diverge from the canonical pathway at the level of Axin, which binds to MEKK1 directly [23]. However, we failed to detect stimulation of PJNK, PJun63, and PJun73 by Axin or dnAxin that contains all the necessary domains required to activate JNK/SAPK as reported previously [23]. Recent reports showed that ectopic expression of Axin1 modulates the JNK/SAPK activity affecting embryonic dorsoventral patterning [59] and that the Axin-dependent JNK/SAPK activation might contribute to the dominant-negative phenotypes of the AxinFu allele [60]. Nevertheless, there is still a lack of in vivo evidence to support the notion that Axin is essential for JNK/SAPK activation. We also did not find any alterations of the JNK/SAPK pathway in the Axin2-null mutants during skull morphogenesis (Liu and Hsu, unpublished observations). Whether the loss of JNK/SAPK activation contributed to the phenotypic defects caused by the disruption of Axin1 [40] or Axin2 [33] remains obscure. The present study suggests that a stress-activated pathway parallel to Wnt/β-catenin is necessary for the stimulation of JNK/SAPK signaling in squamous metaplasia. However, we are not able to rule out the possibility that this signaling converged at some point with the Wnt pathway, or modulated its signaling, to induce squamous differentiation. The signaling event might be modulated at the level upstream of Axin, e.g., Dsh/Dvl [25,61]. Diversin, shown to function as a molecular switch to suppress Wnt/β-catenin while promoting Wnt/JNK, is another candidate [62]. Future investigation focusing on the cooperation of the Wnt/β-catenin and Wnt/JNK signaling cascades promises important insight into the mechanism underlying normal development and pathogenesis of human diseases. Acknowledgments The authors thank Dirk Bohmann, Rudolf Grosschedl, and Arnold Levine for reagents and Anthony Mirando for critical reading of the manuscript. Footnotes 1This work was supported by National Institutes of Health grant CA106308 to W.H. References 1. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810. [PubMed] 2. Clevers H. Wnt/β-catenin signaling in development and disease. Cell. 2006;127:469–480. [PubMed] 3. Perez-Moreno M, Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell. 2006;11:601–612. [PubMed] 4. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of β-catenin. Curr Opin Genet Dev. 2006;16:51–59. [PubMed] 5. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev Cell. 2003;5:367–377. [PubMed] 6. He X. A Wnt-Wnt situation. Dev Cell. 2003;4:791–797. [PubMed] 7. Stadeli R, Hoffmans R, Basler K. Transcription under the control of nuclear Arm/β-catenin. Curr Biol. 2006;16:R378–R385. [PubMed] 8. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2004;9:119–131. [PubMed] 9. Robinson GW, Hennighausen L, Johnson PF. Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev. 2000;14:889–894. [PubMed] 10. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell. 1988;55:619–625. [PubMed] 11. Lane TF, Leder P. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene. 1997;15:2133–2144. [PubMed] 12. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P. ΔN89β-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol. 2001;153:555–568. [PubMed] 13. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994;369:669–671. [PubMed] 14. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987;49:465–475. [PubMed] 15. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP, Weinberg RA. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 2000;14:650–654. [PubMed] 16. Roarty K, Serra R. Wnt5a is required for proper mammary gland development and TGF-β-mediated inhibition of ductal growth. Development. 2007;134:3929–3939. [PubMed] 17. Hsu W, Shakya R, Costantini F. Impaired mammary gland and lymphoid development caused by inducible expression of Axin in transgenic mice. J Cell Biol. 2001;155:1055–1064. [PubMed] 18. Tepera SB, McCrea PD, Rosen JM. A β-catenin survival signal is required for normal lobular development in the mammary gland. J Cell Sci. 2003;116:1137–1149. [PubMed] 19. van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, Bruhn L, Grosschedl R. Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev. 1994;8:2691–2703. [PubMed] 20. Kohn AD, Moon RT. Wnt and calcium signaling: β-catenin-independent pathways. Cell Calcium. 2005;38:439–446. [PubMed] 21. Katoh M. WNT/PCP signaling pathway and human cancer (review). Oncol Rep. 2005;14:1583–1588. [PubMed] 22. Klingensmith J, Nusse R, Perrimon N. The Drosophila segment polarity gene dishevelled encodes a novel protein required for response to the wingless signal. Genes Dev. 1994;8:118–130. [PubMed] 23. Zhang Y, Neo SY, Wang X, Han J, Lin SC. Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. J Biol Chem. 1999;274:35247–35254. [PubMed] 24. Fagotto F, Jho E, Zeng L, Kurth T, Joos T, Kaufmann C, Costantini F. Domains of axin involved in protein-protein interactions, Wnt pathway inhibition, and intracellular localization. J Cell Biol. 1999;145:741–756. [PubMed] 25. Boutros M, Paricio N, Strutt DI, Mlodzik M. Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling. Cell. 1998;94:109–118. [PubMed] 26. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31:99–109. [PubMed] 27. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA. 1998;95:14717–14722. [PubMed] 28. Galceran J, Hsu SC, Grosschedl R. Rescue of a Wnt mutation by an activated form of LEF-1: regulation of maintenance but not initiation of Brachyury expression. Proc Natl Acad Sci USA. 2001;98:8668–8673. [PubMed] 29. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science. 1995;269:403–407. [PubMed] 30. Leppa S, Saffrich R, Ansorge W, Bohmann D. Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. EMBO J. 1998;17:4404–4413. [PubMed] 31. Yu HM, Liu B, Costantini F, Hsu W. Impaired neural development caused by inducible expression of Axin in transgenic mice. Mech Dev. 2007;124:146–156. [PubMed] 32. Yu HM, Liu B, Chiu SY, Costantini F, Hsu W. Development of a unique system for spatiotemporal and lineage-specific gene expression in mice. Proc Natl Acad Sci USA. 2005;102:8615–8620. [PubMed] 33. Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, Puzas JE, Birchmeier W, Hsu W. The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development. 2005;132:1995–2005. [PubMed] 34. Liu B, Yu HM, Hsu W. Craniosynostosis caused by Axin2 deficiency is mediated through distinct functions of β-catenin in proliferation and differentiation. Dev Biol. 2007;301:298–308. [PubMed] 35. Hsu W, Zeng L, Costantini F. Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem. 1999;274:3439–3445. [PubMed] 36. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988. p. xiii. 726 p. 37. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999;96:5522–5527. [PubMed] 38. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422–426. [PubMed] 39. Miyoshi K, Meyer B, Gruss P, Cui Y, Renou JP, Morgan FV, Smith GH, Reichenstein M, Shani M, Hennighausen L, et al. Mammary epithelial cells are not able to undergo pregnancy-dependent differentiation in the absence of the helix-loop-helix inhibitor Id2. Mol Endocrinol. 2002;16:2892–2901. [PubMed] 40. Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL, 3rd, Lee JJ, Tilghman SM, Gumbiner BM, Costantini F. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 1997;90:181–192. [PubMed] 41. Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene. 2007;26:3172–3184. [PubMed] 42. Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature. 1994;372:798–800. [PubMed] 43. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. β-Catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 1998;58:3526–3528. [PubMed] 44. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G, Prat J, Guo M, Herman JG, Matias-Guiu X, et al. Abnormalities of the APC/β-catenin pathway in endometrial cancer. Oncogene. 2002;21:7981–7990. [PubMed] 45. Saegusa M, Okayasu I. Frequent nuclear β-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol. 2001;194:59–67. [PubMed] 46. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett. 2005;222:1–10. [PubMed] 47. Daniel VC, Peacock CD, Watkins DN. Developmental signalling pathways in lung cancer. Respirology. 2006;11:234–240. [PubMed] 48. Scholten AN, Creutzberg CL, van den Broek LJ, Noordijk EM, Smit VT. Nuclear β-catenin is a molecular feature of type I endometrial carcinoma. J Pathol. 2003;201:460–465. [PubMed] 49. Bierie B, Nozawa M, Renou JP, Shillingford JM, Morgan F, Oka T, Taketo MM, Cardiff RD, Miyoshi K, Wagner KU, et al. Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene. 2003;22:3875–3887. [PubMed] 50. Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M. Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci. 2003;94:593–597. [PubMed] 51. Vuong H, Patterson T, Shapiro P, Kalvakolanu DV, Wu R, Ma WY, Dong Z, Kleeberger SR, Reddy SP. Phorbol ester-induced expression of airway squamous cell differentiation marker, SPRR1B, is regulated by protein kinase Cδ/Ras/MEKK1/MKK1-dependent/AP-1 signal transduction pathway. J Biol Chem. 2000;275:32250–32259. [PubMed] 52. Vuong H, Patterson T, Adiseshaiah P, Shapiro P, Kalvakolanu DV, Reddy SP. JNK1 and AP-1 regulate PMA-inducible squamous differentiation marker expression in Clara-like H441 cells. Am J Physiol Lung Cell Mol Physiol. 2002;282:L215–L225. [PubMed] 53. Zhong CY, Zhou YM, Douglas GC, Witschi H, Pinkerton KE. MAPK/AP-1 signal pathway in tobacco smoke-induced cell proliferation and squamous metaplasia in the lungs of rats. Carcinogenesis. 2005;26:2187–2195. [PubMed] 54. Lemjabbar-Alaoui H, Dasari V, Sidhu SS, Mengistab A, Finkbeiner W, Gallup M, Basbaum C. Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PLoS ONE. 2006;1:e93. [PubMed] 55. Shu W, Jiang YQ, Lu MM, Morrisey EE. Wnt7b regulates mesenchymal proliferation and vascular development in the lung. Development. 2002;129:4831–4842. [PubMed] 56. Shu W, Guttentag S, Wang Z, Andl T, Ballard P, Lu MM, Piccolo S, Birchmeier W, Whitsett JA, Millar SE, et al. Wnt/β-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung. Dev Biol. 2005;283:226–239. [PubMed] 57. De Langhe SP, Sala FG, Del Moral PM, Fairbanks TJ, Yamada KM, Warburton D, Burns RC, Bellusci S. Dickkopf-1 (DKK1) reveals that fibronectin is a major target of Wnt signaling in branching morphogenesis of the mouse embryonic lung. Dev Biol. 2005;277:316–331. [PubMed] 58. Okubo T, Hogan BL. Hyperactive Wnt signaling changes the developmental potential of embryonic lung endoderm. J Biol. 2004;3:11. [PubMed] 59. Rui Y, Xu Z, Xiong B, Cao Y, Lin S, Zhang M, Chan SC, Luo W, Han Y, Lu Z, et al. A β-catenin-independent dorsalization pathway activated by Axin/JNK signaling and antagonized by aida. Dev Cell. 2007;13:268–282. [PubMed] 60. Lu Z, Liu W, Huang H, He Y, Han Y, Wang Y, Li Q, Ruan K, Ye Z, Low BC, et al. Protein encoded by the AxinFu allele effectively downregulates Wnt signaling but exerts a dominant negative effect on c-Jun N-terminal kinase signaling. J Biol Chem. 2008 61. Yanagawa S, van Leeuwen F, Wodarz A, Klingensmith J, Nusse R. The dishevelled protein is modified by wingless signaling in Drosophila. Genes Dev. 1995;9:1087–1097. [PubMed] 62. Schwarz-Romond T, Asbrand C, Bakkers J, Kuhl M, Schaeffer HJ, Huelsken J, Behrens J, Hammerschmidt M, Birchmeier W. The ankyrin repeat protein Diversin recruits casein kinase Iε to the β-catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling. Genes Dev. 2002;16:2073–2084. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Annu Rev Cell Dev Biol. 2004; 20():781-810.
[Annu Rev Cell Dev Biol. 2004]Cell. 2006 Nov 3; 127(3):469-80.
[Cell. 2006]Dev Cell. 2006 Nov; 11(5):601-12.
[Dev Cell. 2006]Curr Opin Genet Dev. 2006 Feb; 16(1):51-9.
[Curr Opin Genet Dev. 2006]Dev Cell. 2003 Sep; 5(3):367-77.
[Dev Cell. 2003]J Mammary Gland Biol Neoplasia. 2004 Apr; 9(2):119-31.
[J Mammary Gland Biol Neoplasia. 2004]Genes Dev. 2000 Apr 15; 14(8):889-94.
[Genes Dev. 2000]Cell. 1988 Nov 18; 55(4):619-25.
[Cell. 1988]Oncogene. 1997 Oct; 15(18):2133-44.
[Oncogene. 1997]J Cell Biol. 2001 Apr 30; 153(3):555-68.
[J Cell Biol. 2001]Cell Calcium. 2005 Sep-Oct; 38(3-4):439-46.
[Cell Calcium. 2005]Oncol Rep. 2005 Dec; 14(6):1583-8.
[Oncol Rep. 2005]Oncol Rep. 2005 Dec; 14(6):1583-8.
[Oncol Rep. 2005]Genes Dev. 1994 Jan; 8(1):118-30.
[Genes Dev. 1994]J Biol Chem. 1999 Dec 3; 274(49):35247-54.
[J Biol Chem. 1999]Cell. 1982 Nov; 31(1):99-109.
[Cell. 1982]Proc Natl Acad Sci U S A. 1998 Dec 8; 95(25):14717-22.
[Proc Natl Acad Sci U S A. 1998]Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8668-73.
[Proc Natl Acad Sci U S A. 2001]Science. 1995 Jul 21; 269(5222):403-7.
[Science. 1995]EMBO J. 1998 Aug 3; 17(15):4404-13.
[EMBO J. 1998]Mech Dev. 2007 Feb; 124(2):146-56.
[Mech Dev. 2007]Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8615-20.
[Proc Natl Acad Sci U S A. 2005]J Cell Biol. 2001 Dec 10; 155(6):1055-64.
[J Cell Biol. 2001]Development. 2005 Apr; 132(8):1995-2005.
[Development. 2005]Dev Biol. 2007 Jan 1; 301(1):298-308.
[Dev Biol. 2007]Proc Natl Acad Sci U S A. 1999 May 11; 96(10):5522-7.
[Proc Natl Acad Sci U S A. 1999]Nature. 1999 Apr 1; 398(6726):422-6.
[Nature. 1999]Nature. 1994 Jun 23; 369(6482):669-71.
[Nature. 1994]Mol Endocrinol. 2002 Dec; 16(12):2892-901.
[Mol Endocrinol. 2002]Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8668-73.
[Proc Natl Acad Sci U S A. 2001]Cell. 1997 Jul 11; 90(1):181-92.
[Cell. 1997]J Biol Chem. 1999 Dec 3; 274(49):35247-54.
[J Biol Chem. 1999]Oncogene. 2007 May 14; 26(22):3172-84.
[Oncogene. 2007]Nature. 1994 Dec 22-29; 372(6508):798-800.
[Nature. 1994]Proc Natl Acad Sci U S A. 1998 Dec 8; 95(25):14717-22.
[Proc Natl Acad Sci U S A. 1998]Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8668-73.
[Proc Natl Acad Sci U S A. 2001]Science. 1995 Jul 21; 269(5222):403-7.
[Science. 1995]Cancer Res. 1998 Aug 15; 58(16):3526-8.
[Cancer Res. 1998]Oncogene. 2002 Nov 14; 21(52):7981-90.
[Oncogene. 2002]J Pathol. 2001 May; 194(1):59-67.
[J Pathol. 2001]Cancer Lett. 2005 May 10; 222(1):1-10.
[Cancer Lett. 2005]Respirology. 2006 May; 11(3):234-40.
[Respirology. 2006]J Cell Biol. 2001 Apr 30; 153(3):555-68.
[J Cell Biol. 2001]J Cell Biol. 2001 Dec 10; 155(6):1055-64.
[J Cell Biol. 2001]J Cell Sci. 2003 Mar 15; 116(Pt 6):1137-49.
[J Cell Sci. 2003]Cell. 1988 Nov 18; 55(4):619-25.
[Cell. 1988]Nature. 1994 Jun 23; 369(6482):669-71.
[Nature. 1994]Cancer Sci. 2003 Jul; 94(7):593-7.
[Cancer Sci. 2003]J Biol Chem. 2000 Oct 13; 275(41):32250-9.
[J Biol Chem. 2000]Am J Physiol Lung Cell Mol Physiol. 2002 Feb; 282(2):L215-25.
[Am J Physiol Lung Cell Mol Physiol. 2002]Carcinogenesis. 2005 Dec; 26(12):2187-95.
[Carcinogenesis. 2005]PLoS One. 2006 Dec 20; 1():e93.
[PLoS One. 2006]